Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol + Methotrexate in Early Active Rheumatoid Arthritis
NCT01521923Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2012
- Primary completion
- Jul 2015
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (3 arms), sponsored by UCB. Primary endpoint: Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] <= 3.2 Without Flaring at 104 weeks. Started Jan 2012; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01521923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01521923.